



Euro PhD Network


P Ehrlich  
MedChem



OHD  
ONE  
HEALTH  
DRUGS

**33<sup>rd</sup> GP<sub>2</sub>A Annual Medicinal Chemistry Conference,  
XIV<sup>th</sup> Paul Ehrlich MedChem Euro-PhD Network Meeting  
& COST Action One Health drugs against parasitic vector borne  
diseases in Europe and beyond (OneHealthdrugs)**

**Nantes Université - France**



**MINUTES**

The **33<sup>rd</sup> Annual GP<sub>2</sub>A** (Group for the Promotion of Pharmaceutical chemistry in Academia) **Conference** was officially opened with a warm welcome to all participants at Nantes Université. This year's edition was marked by a significant milestone, as GP<sub>2</sub>A proudly partnered with the **COST Action OneHealthdrugs** and the **Paul Ehrlich Euro-PhD Network**. This joint initiative successfully fostered new collaborations, broadened perspectives, and laid the groundwork for future directions in pharmaceutical research.

As anticipated, the scientific programme featured a distinguished line-up of keynote speakers, complemented by engaging and well-attended social events. The Organising Committee extends its sincere thanks to the local members for their outstanding commitment and contributions: Assoc. Prof. Marc-Antoine Bazin, Tatiana Bernoussi, Justine Bonnet, Céline Lhomelet, Assoc. Prof. Cédric Logé, Prof. Pascal Marchand, Assoc. Prof. Isabelle Ourliac-Garnier, Prof. Jean-Michel Robert, Mathieu Scaviner, Jérôme Thiéfaine and Dr. Thomas Yvorra.

A strong presence of postgraduate students once again underscored the importance of nurturing the next generation of researchers. As part of GP<sub>2</sub>A's ongoing commitment to advanced research training, a pre-conference workshop on Artificial Intelligence in Drug Discovery was held. Dr. Dylan Sérillon led this highly interactive session, providing hands-on training to **51 attendees** on emerging AI tools and methodologies in pharmaceutical sciences.

The scientific programme commenced with presentations from **8 invited international experts**, who addressed recent advances in applied medicinal chemistry. Their talks covered a wide range of topics, including infectious and neurodegenerative diseases, polypharmacology, sustainable development, and strategies to tackle undruggable targets.

This year's conference welcomed **168 participants** and featured **102 abstracts**. Sessions explored diverse themes such as cancer chemotherapeutics, protein degradation, target identification, hit discovery and optimisation, natural products, inflammatory diseases, cheminformatics, AI and machine learning applications, as well as innovative synthetic approaches.

A notable highlight was the Thursday morning session dedicated to **COST Action OneHealthdrugs**, which was met with strong interest and attendance.

Upholding GP<sub>2</sub>A's ethos of promoting early-career scientists, the conference provided a platform for **25 oral communications** by young researchers, alongside **25 flash poster presentations** and **77 posters** presented across three sessions. These contributions were considered for various conference awards and were critical in promoting dialogue between junior and senior researchers.

The Organising Committee extends its heartfelt appreciation to all speakers, participants, and sponsors for their enthusiastic support and engagement in making the joint Conference a resounding success.

Participants are invited to save the date for the **34<sup>th</sup> Annual GP<sub>2</sub>A Conference**, which will take place in **Gothenburg, Sweden, from August 26<sup>th</sup> to 28<sup>th</sup>, 2026!**